The inflammation control not only in the central airway, but also in the peripheral airways is important to achieve total asthma control.
Introduction Introduction
To evaluate the inhalants deposition to the lung of Japanese asthma patients by FRI and to analyze the factors influencing to deposition in the peripheral airway based on the pooled data.
Aim Aim

Methods Methods
Single-center, open-label study (UMIN000022840)
This study was conducted in compliance with ethical and scientific principles based on the Declaration of Helsinki (revised in Fortaleza in 2013), the Ethical 
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Results Results
Conclusion Conclusion
Flutiform (pMDI) was shown to provide significantly higher drug deposition to the peripheral airways than Symbicort (DPI) and Relvar (DPI).
Significant correlation between deposition and FPF of the drugs were found in peripheral airways.
There was no correlation between deposition and respiratory function values except for FEV1 in Flutiform.
It is suggested that Flutiform (pMDI) may provide a potent therapeutic option to the peripheral airway for various asthma patients without being affected by peripheral airway parameters, including those who have difficulty using DPIs. 
